Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies (Q43614860)

25 November 2017

title

Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies (English)

1 reference

25 November 2017

0 references

1 reference

4

Ulf Dittmer

1 reference

25 November 2017

Wibke Bayer

1

1 reference

25 November 2017

Simone Schimmer

series ordinal

2

1 reference

25 November 2017

Dennis Hoffmann

series ordinal

3

1 reference

25 November 2017

Oliver Wildner

series ordinal

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

5 December 2007

1 reference

25 November 2017

number of pages

11

1 reference

inferred from page(s)

published in

Vaccine

1 reference

25 November 2017

volume

26

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

716-726

1 reference

Progress and obstacles in the development of an AIDS vaccine

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

A review of vaccine research and development: the human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

No vaccine against HIV yet--are we not perfectly equipped?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Animal models used for the evaluation of antiretroviral therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Current concepts in AIDS pathogenesis: insights from the SIV/macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunity to retroviral infection: the Friend virus model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

A major genetic locus affecting resistance to infection with murine leukemia viruses. II. Apparent identity to a major locus described for resistance to friend murine leukemia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

The effect of histocompatibility-2 type on response to friend leukemia virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunoprotective determinants in friend murine leukemia virus envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Role of natural killer cells in resistance against friend retrovirus-induced leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunoprevention of Friend leukaemia virus-induced erythroleukaemia by vaccination with aggregated gp70.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

A simplified system for generating recombinant adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

AIDS research. Promising AIDS vaccine's failure leaves field reeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

7 January 2021

Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

7 January 2021

Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

7 January 2021

Protection against establishment of retroviral persistence by vaccination with a live attenuated virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

7 January 2021

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.050

7 January 2021

10.1016/J.VACCINE.2007.11.050

Identifiers

DOI

1 reference

25 November 2017

1 reference